Juno Therapeutics‘ (NASDAQ: JUNO) CAR-T cancer research program has been recently plagued by safety concerns, and that could give other companies working on CAR-T therapies an edge. Can Kite Pharma (NASDAQ: KITE) and Bellicum Pharmaceuticals (NASDAQ: BLCM) sidestep the risks that temporarily halted Juno Therapeutics’ JCAR015 study?